Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the s...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bhutani D, Zonder JA
Format: article
Langue:EN
Publié: Dove Medical Press 2017
Sujets:
Accès en ligne:https://doaj.org/article/3d0a108b5d134eb4907426eb0441eb80
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!